Oncogenic FGFR3 fusions (with TACC3 as the most frequent partner gene) are found in up to 2% to 3% of bladder cancer and detected in upper tract urothelial carcinoma as well (2, 4–6). Here, FGFR3 is linked to urinary bladder cancer.